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Abstract
OBJECTIVE—To evaluate the effect of baseline bleeding patterns on rates of amenorrhea 
reported at 12 months in LNG (levonorgestrel) 52 mg IUS (intrauterine system) users. We also 
assessed the effect of baseline bleeding patterns at three and six months post-insertion.
STUDY DESIGN—In this secondary analysis of the Contraceptive CHOICE Project, we included 
participants who had a LNG-IUS inserted within one month of enrollment and continued use for 
12 months. Using 12-month telephone survey data, we defined amenorrhea at 12 months of use as 
no bleeding or spotting during the previous six months. We used chi-square and multivariable 
logistic regression to assess the association of baseline bleeding pattern with amenorrhea while 
controlling for confounding variables.
RESULTS—Of 1802 continuous 12-month IUS users, amenorrhea was reported by 4.9%, 14.8% 
and 15.4% of participants at three, six, and 12 months, receptively. Participants with light baseline 
bleeding or short duration of flow reported higher rates of amenorrhea at three and six months 
post-insertion (p<0.03), while LNG-IUS users with heavy or prolonged flow were less likely to 
report amenorrhea at 3 and 6 months (p<0.03). In a multivariable analysis, participants with self-
reported heavy bleeding at baseline were less likely to report amenorrhea at 12 months than those 
who reported moderate bleeding (ORadj, 0.36; 95% CI, 0.16–0.69).
CONCLUSION—Women with heavier menstrual bleeding are less likely than women with 
moderate flow to report amenorrhea following 12 months of LNG-IUS use.
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INTRODUCTION
The levonorgestrel-releasing intrauterine system (LNG-IUS) is one of the most effective 
long-acting reversible contraceptive (LARC) methods, and its effectiveness is not user-
dependent [1,2]. The LNG-IUS causes changes in menstrual bleeding patterns by altering 
endometrial histology; characteristic changes include endometrial thinning and stromal and 
glandular atrophy [3]. As such, one documented non-contraceptive benefit is potential 
amenorrhea. Reportedly, nearly 20% of women will become amenorrheic within one year of 
insertion with increasing rates of over time [4–6]. Changes in bleeding patterns may have 
varying levels of desirability, affecting the choice to continue or discontinue method use [7]. 
However, most women see amenorrhea as a beneficial side effect [8].
Previous studies have suggested possible predictors of amenorrhea after LNG-IUS use, such 
as small uterine cavity measurements and the absence of heavy bleeding prior to insertion 
[9–10]. Body mass index (BMI) has also been investigated with mixed results [11]. 
However, there is still a relative lack of data regarding women’s baseline bleeding patterns 
as a predictor of amenorrhea.
The purpose of this study is to examine the association of baseline bleeding patterns on 
amenorrhea at 12 months in levonorgestrel 52 mg intrauterine system (LNG-IUS) users. We 
hypothesized that women with self-reported light (10 or fewer pads or tampons per 
menstrual cycle) and short (less than four days per month) baseline bleeding patterns would 
be more likely to experience amenorrhea at 12 months following LNG-IUS insertion than 
those with moderate amount (11–20 pads or tampons) and duration (four to six days per 
month) of flow.
METHODS
The Contraceptive CHOICE Project (CHOICE) is a prospective cohort study of 9256 
women from the St. Louis region who were provided with reversible contraception at no cost 
for two to three years. The methods have been previously published [12]. This study 
represents a secondary analysis of participants who chose and received a LNG-IUS at 
baseline enrollment.
Briefly, we recruited CHOICE participants from specific clinic locations in the St. Louis 
region between 2007–2011 and deemed eligible to participate if they were 14–45 years of 
age, sexually active or anticipated sexual activity with a male partner in the next six months, 
and did not desire pregnancy in the year following enrollment. Prior to enrollment, we 
obtained written informed consent from every participant.
For this analysis, only women who chose and received the LNG IUS within one month of 
enrollment and continued using the method for 12 months are included. We included 
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participants with complete data on baseline bleeding patterns at three, six and 12 months. In 
addition, we excluded women if data about their baseline contraceptive use was missing, as 
contraceptive method prior to LNG-IUS insertion can affect menstrual cycle characteristics.
Upon enrollment, we assessed baseline bleeding patterns with several questions. 
Specifically, participants were asked to describe the average heaviness of bleeding during 
their period and the average length of their period during the previous 12 months. Participant 
responses for heaviness of bleeding were categorized as light, moderate, moderately heavy, 
heavy, or too variable or irregular to say. To assist the participant in choosing the answer 
most representative of their menstrual flow, survey responses were clarified by estimating 
the number of pads or tampons used per cycle (10 or fewer, 11–20, 21–30, more than 30, 
respectively). Responses for length of period were one to three days, four to six days, seven 
to nine days, 10 days or longer, or too variable or irregular to say. We defined a normal 
baseline bleeding pattern as only moderate flow and four to six days of bleeding [13].
We performed follow-up telephone interviews at three and six months, and then every 6 
months thereafter. Participants were asked if and how their bleeding patterns had changed, as 
well as if menstruation ceased during the time between surveys. We assessed bleeding at 
three, six, and 12-months. At three and six months, we asked participants if they had any 
bleeding or spotting since the baseline or three-month survey, respectively. At the 12-month 
survey, participants were asked if they had any bleeding or spotting since the six-month 
survey. Our primary outcome was self-reported amenorrhea at 12 months, defined as no 
bleeding or spotting since the six-month interview. Although there is not one uniform 
definition of amenorrhea, many experts suggest 90 days of no bleeding or three missed 
menstrual cycles. We chose six months of no bleeding as our definition to be more 
conservative and consistent with the language used in the CHOICE surveys.
Because selecting only women who continued their method and completed all surveys at 
three, six, and 12 months may create selection bias, we performed two analyses. First, we 
evaluated women who continued LNG-IUS use and answered all surveys for 12 months, and 
second, women who continued use and answered any, but not necessarily all, of the surveys 
up to 12 months. The results for both evaluations did not vary so we only present data from 
our primary analysis with complete survey data.
We evaluated the relationship between baseline bleeding and self-reported amenorrhea at 12 
months with bivariate analysis using chi-square for all categorical variables. Factors with a 
p-value less than or equal to 0.1 were included in the multivariate model. We defined 
confounders as variables that changed the odds ratio by ≥10% when added to the logistic 
regression model [14]. We included all resulting confounding factors significantly associated 
with amenorrhea in the final multivariable model. SPSS, version 22 was used for all 
statistical analyses. The statistical significance level was set at 0.05.
RESULTS
Of 9256 total CHOICE participants, 3317 chose and initiated LNG-IUS use within one 
month of enrollment. We excluded 223 women with missing baseline bleeding data, one 
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with missing baseline contraceptive data, and 292 for not continuing LNG-IUS use for 12 
months. We excluded another 999 women enrolled prior to addition of the bleeding 
questions at three through 12 months. Of the remaining 2094 women, 1802 provided 
bleeding data and continued LNG-IUS use through 12 months, comprising our primary 
cohort. The sample size differed by 267 participants between participants who completed all 
follow-up surveys and those who completed some, but not all, as described in the methods 
section. Our final analytic sample consisted of 1802 participants who had complete 
information regarding baseline bleeding pattern and contraceptive use, as well as continued 
use of the LNG-IUS and 12-month survey data. At three months, 88 participants (4.9%) 
reported no bleeding or spotting in the prior three months. At six months, 266 (14.8%) users 
reported no bleeding or spotting in the prior three months, and at 12 months, 278 (15.4%) 
reported no bleeding or spotting in the past six months.
Baseline demographic characteristics, stratified by amenorrhea status at 12 months, are 
shown in Table 1. Our sample was racially and ethically diverse; 45.1% were black and 
4.3% were of Hispanic descent. Over half of our sample was under the age of 25. In our 
unadjusted analyses, age, race, gravidity, parity, contraceptive use at time of enrollment, 
BMI and history of sexually transmitted infection (STI) were found to be significantly 
associated with amenorrhea at 12 months. In our adjusted analyses, black women and 
women of other races, compared to white women, were less likely to be amenorrheic (ORadj 
0.62; CI 0.45–0.86 and ORadj 0.55; CI 0.31–0.98, respectively), as were those with gravidity 
of three or greater (ORadj 0.65; CI 0.43–0.99).
One in five women (21.0%, n=74/353) with light bleeding at baseline reported amenorrhea 
at 12 months compared to 16.3% (n=166/1019) of those with moderate, 10.0% (n=29/292) 
of those with moderately heavy, and 5.2% (n=7/134) of those with heavy bleeding 
(p<0.001). A similar overall trend is apparent at 12 months when considering length of 
bleeding, although this latter association is not significant (p=0.10). Amenorrhea rates at 
three and six months also demonstrated an association with baseline bleeding patterns (Table 
2). Participants with lighter bleeding and shorter duration of bleeding were more likely to 
report amenorrhea at three and six months following insertion.
Age, ethnicity, marital status, education level, contraceptive use at the time of enrollment, 
BMI and history of STI did not alter the association between baseline bleeding patterns and 
amenorrhea. However, race and gravidity remained significant confounders, and therefore 
are included in the multivariable analysis. In our final multivariable model (Table 3), 
participants with self-reported moderately heavy or heavy bleeding at baseline were less 
likely to experience amenorrhea at 12 months than the reference category of moderate 
bleeding (ORadj, 0.60; CI, 0.39–0.93 and ORadj, 0.36; CI, 0.16–0.69, respectively).
DISCUSSION
We found that women with heavier menstrual flow at baseline were less likely to become 
amenorrheic at 12 months after LNG-IUS insertion. Overall rates of amenorrhea increased 
as time since insertion progressed from three to 12 months. We also found race and gravidity 
to have a small effect in the final model. One reason race may have been significantly 
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associated with heavier bleeding in our analysis may be related to a higher prevalence of 
uterine leiomyomata in black women, which can be associated with heavy menstrual flow 
[15]. We also noted that participants who report light flow and shorter durations of bleeding 
were more likely to report amenorrhea at three and six months post-insertion.
The LNG-IUS has characteristic and well-described hormonal effects on the endometrium, 
such as atrophy of endometrial glands and stromal decidualization [16]. These changes can 
become apparent as soon as one month after insertion and are maintained for as long as 
seven years, with a significant decrease in endometrial thickness by 10 weeks on pathologic 
examination [17]. As the effects of the LNG-IUS shift the endometrium from its normal 
cycling to a more inactive state, initial bleeding and spotting irregularities occur, followed by 
overall lighter bleeding [18].
We speculate that women with minimal baseline menstrual bleeding or shorter duration of 
flow may have a thinner endometrial lining than a woman with heavy, or even average, 
bleeding. These women may be more likely to experience amenorrhea with LNG-IUS use 
than women with normal or heavier flow. Jensen and colleagues [19] noted that LNG-IUS 
insertion in women with heavy menstrual bleeding resulted in lower than expected rates of 
amenorrhea at one year of use. Another report noted that post-abortion LNG-IUS insertion 
resulted in more favorable bleeding patterns compared to post-menstrual placement, perhaps 
due to most endometrial tissue being removed during the procedure [4].
An important strength of this study is the reproductive and demographic diversity of the 
participants. Additionally, our analysis had a large sample size of nearly 2000 women. These 
women chose their own contraceptive method and were not randomly assigned, which more 
realistically reflects the clinical setting. Notably, these women received their method 
specifically for contraception and not for management of menstrual bleeding. Finally, we 
had excellent follow-up rates (95% follow-up at 12 months and 87% at 24 months for 
CHOICE overall [20]), allowing us to maintain a large sample size by the 12-month follow-
up survey.
Our analysis is not without limitation. One weakness of our analysis is our definition of 
amenorrhea. Elsewhere in the literature, amenorrhea is defined as no bleeding or spotting for 
three months [4,5]; our 12-month survey asked about bleeding over the previous six-month 
period instead. Our six-month definition was more stringent than the usual cut-off due to the 
language of the CHOICE surveys, potentially explaining why our rate of amenorrhea was 
lower than previous reported literature (14.5% vs. 20%) [4]. Notably, our definition of 
amenorrhea at three and six-month time points was still consistent with the traditional 
definition. Other weaknesses of this analysis include lack of information regarding uterine 
fibroids and subjective recall of bleeding patterns using telephone surveys as opposed to 
prospective collection with bleeding diaries. However, we feel that collection of diaries with 
such a large sample size would have been challenging and impractical. We believe the 
survey questions sufficiently assessed bleeding patterns and reflect participants’ general 
bleeding trends. In addition, our approach of assessing bleeding patterns through participant 
recall is consistent with clinical scenarios.
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Our results show that baseline bleeding pattern has a significant association with the 
likelihood of amenorrhea at 12 months. This knowledge may influence patients’ 
contraceptive choice and practitioners’ counseling. Anticipatory counseling, in the context 
of bleeding patterns and other predictors, may improve user satisfaction and continuation of 
the LNG-IUS. Efforts to improve continuation and satisfaction are an important strategy to 
continue to reduce unintended pregnancy and abortion rates.
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IMPLICATIONS
Baseline heavy menstrual flow reduces the likelihood of amenorrhea with LNG-IUS use, 
information which could impact contraceptive counseling; anticipatory counseling can 
improve method satisfaction and continuation, an important strategy to continue to reduce 
unintended pregnancy and abortion rates.
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Table 1
Baseline characteristics of participants receiving LNG-IUS stratified by amenorrheic status at 12 months 
(n=1802)
Characteristic Total (n=1802) Amenorrheic at 12 months 
(n=278)
Non-amenorrheic at 12 
months (n=1524)
p-value
Age <0.01
 <18 42 (2.3) 10 (3.6) 32 (2.1)
 18–20 209 (11.6) 31 (11.2) 178 (11.7)
 21–25 720 (40.0) 126 (45.3) 594 (39.0)
 26–30 465 (25.8) 75 (27.0) 390 (25.6)
 >30 366 (20.3) 36 (12.9) 330 (21.7)
Race <0.01
 Black 814 (45.1) 88 (31.7) 726 (47.6)
 White 855 (47.4) 174 (62.6) 681 (44.7)
 Other 133 (7.4) 16 (5.8) 117 (7.7)
Hispanic ethnicity 78 (4.3) 11 (4.0) 67 (4.4) 0.74
Marital status 0.43
 Single/never married 1041 (57.8) 169 (60.8) 872 (57.3)
 Married/living with partner 638 (35.4) 94 (33.8) 544 (35.7)
 Separated/divorced/widowed 122 (6.8) 15 (5.4) 107 (7.0)
Education level 0.18
 < High school 462 (25.6) 61 (21.9) 401 (26.3)
 Some college 801 (44.5) 123 (44.2) 678 (44.5)
 College/grad 538 (29.9) 94 (33.8) 444 (29.2)
Gravidity <0.01
 0 515 (28.6) 120 (43.2) 395 (25.9)
 1 370 (20.5) 53 (19.1) 317 (20.8)
 2 341 (18.9) 46 (16.5) 295 (19.4)
 ≥3 576 (31.9) 59 (21.2) 517 (33.9)
Prior contraceptive use at time of enrollment <0.01
 PPR 522 (29.0) 111 (39.9) 411 (27.0)
 LARC (IUD or implant) 23 (1.3) 1 (0.4) 22 (1.4)
 DMPA 31 (1.7) 4 (1.4) 27 (1.8)
 Other 708 (39.3) 99 (35.6) 609 (40.0)
 None 518 (28.7) 63 (22.7) 455 (29.9)
BMI (kg/m2) 0.02
 <18.5 41 (2.3) 4 (1.5) 37 (2.5)
 18.5–24.9 666 (37.0) 120 (43.8) 546 (36.2)
 25–29.9 481 (26.7) 78 (28.5) 403 (26.7)
 ≥30 593 (32.9) 72 (26.3) 521 (34.6)
Any history of STI (excluding BV & PID) 705 (39.1) 87 (31.3) 618 (40.6) <0.01
Data are presented as n (%).
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PPR = pill, patch or ring; LARC = long-acting reversible contraception; IUD = intrauterine device; DMPA = depot medroxyprogesterone acetate 
injection
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Table 2
Amenorrhea rates at 3 and 6 months of LNG IUS use stratified by baseline menstrual characteristics (n=1802)
Number at 3 months Amenorrheic at 3 months 
(n=88)
Number at 6 months Amenorrheic at 6 months 
(n=266)
Amount of bleeding
 Light 353 27 (7.7) 353 71 (20.1)
 Moderate 1019 50 (4.9) 1019 146 (14.3)
 Moderately Heavy 292 8 (2.7) 292 36 (12.3)
 Heavy 134 3 (2.2) 134 10 (7.5)
p=0.027 p<0.001
Duration of Flow
 1–3 days 255 23 (9.0) 255 47 (18.4)
 4–6 days 1322 58 (4.4) 1322 195 (14.8)
 ≥7 days 221 7 (3.5) 221 22 (10.0)
p=0.016 p=0.025
Note: p-values in Table 2 represent the association of each baseline bleeding characteristic with amenorrhea at both 3 and 6 months.
Data are presented as n (%).
LNG-IUS = levonorgestrel intrauterine system
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Table 3
Multivariable model of the association between baseline menstrual characteristics and amenorrhea at 12 
months in LNG 52 mg IUS users
Number at 12 months Amenorrheic at 12 months (n=278) OR (95% CI) Crude OR (95% CI) Adjusted*
Amount of bleeding
 Light 353 74 (21.0) 1.36 (1.00–1.85) 1.26 (0.92–1.74)
 Moderate 1019 166 (16.3) Reference
 Moderately Heavy 292 29 (10.0) 0.57 (0.37–0.86) 0.60 (0.39–0.93)
 Heavy 134 7 (5.2) 0.28 (0.13–0.62) 0.36 (0.16–0.69)
Duration of flow
 1–3 days 255 48 (18.8) 1.26 (0.89–1.79) 1.43 (0.99–2.07)
 4–6 days 1322 205 (15.5) Reference
 ≥7 days 221 24 (10.9) 0.66 (0.42–1.04) 0.72 (0.45–1.15)
Adjusted for race and gravidity.
Data are presented as n (%).
LNG-IUS = levonorgestrel intrauterine system
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